MINT 冲刺 2.0：一种图片命名测试，用于检测阿尔茨海默病和临床前 AD 中的命名障碍。
The MINT Sprint 2.0: A picture naming test for detection of naming impairments in Alzheimer's disease and in preclinical AD.
机构信息
Department of Psychiatry, University of California, San Diego, La Jolla, California, USA.
Joint Doctoral Program in Language and Communicative Disorders, San Diego State University/University of California, San Diego, La Jolla, California, USA.
出版信息
Alzheimers Dement. 2024 Jan;20(1):112-123. doi: 10.1002/alz.13381. Epub 2023 Jul 19.
INTRODUCTION
Evidence on the onset of naming deficits in Alzheimer's disease (AD) is mixed. Some studies showed an early decline, but others did not. The present study introduces evidence from a novel naming test.
METHODS
Cognitively normal (n = 138), mild cognitive impairment (MCI; n = 21), and Alzheimer's disease (AD; n = 31) groups completed an expanded Multilingual Naming Test with a time-pressured administration procedure (MINT Sprint 2.0). Cerebrospinal fluid biomarkers classified participants as true controls (n = 61) or preclinical AD (n = 26).
RESULTS
Total correct MINT Sprint 2.0 scores exhibited good sensitivity and specificity (>0.85) for discriminating true controls from cognitively impaired (MCI/AD) groups and showed significant differences between true controls and preclinical AD groups. Time measurement did not improve classification, but percent resolved scores exhibited promise as an independent AD marker.
DISCUSSION
Naming deficits can be detected in the earliest stages of AD with tests and procedures designed for this purpose.
简介
关于阿尔茨海默病（AD）命名缺陷起始时间的证据不一。一些研究显示早期衰退，但其他研究则没有。本研究介绍了一种新命名测试的证据。
方法
认知正常（n=138）、轻度认知障碍（MCI；n=21）和阿尔茨海默病（AD；n=31）组完成了扩展的多语种命名测试，采用限时施测程序（MINT Sprint 2.0）。脑脊液生物标志物将参与者分为真对照组（n=61）或临床前 AD 组（n=26）。
结果
总正确 MINT Sprint 2.0 分数在区分真对照组和认知受损（MCI/AD）组方面具有良好的敏感性和特异性（>0.85），并且在真对照组和临床前 AD 组之间存在显著差异。时间测量并未提高分类效果，但解决比例得分有望成为 AD 的独立标志物。
讨论
命名缺陷可以通过专门为此设计的测试和程序在 AD 的早期阶段检测到。
Zotero 插件